Core Viewpoint - Suzhou Gaoxin plans to sell a 47% stake in Suzhou Medical Device Industry Development Group for 604 million yuan, aiming to reduce the impact of the medical device company's underperformance on its financial statements [1][2]. Group 1: Transaction Details - The transaction price of 604 million yuan is based on an asset valuation report, reflecting a 12.93% premium over the book value of the stake [2]. - The payment will be made in installments, with 51% due by January 7, 2026, and the remaining 49% by March 31, 2026 [2]. - Suzhou Gaoxin's cost basis for the stake was 535 million yuan, indicating a transaction premium [2]. Group 2: Company Performance - Suzhou Medical Device Industry Development Group reported a revenue of 152 million yuan for 2024 and a net loss of approximately 81.81 million yuan [1]. - For the first three quarters of 2025, the company generated 140 million yuan in revenue with a net loss of about 101 million yuan [1]. Group 3: Strategic Implications - The sale is expected to enhance Suzhou Gaoxin's overall profitability by reducing the negative impact of the medical device company's performance on its financials [3]. - The company will continue to manage existing funds and projects while focusing on quality enterprises in the medical device sector and promoting green low-carbon industrial park operations [3].